Bempedoic acid

Studies of bempedoic acid in people

8 studies gave bempedoic acid to people and measured what changed

What changedDesignPeopleSource

down: Lowers the risk of major adverse limb events36%

down: Decreases total major adverse limb events2.9 with bempedoic acid versus 4.0 with placebo

down: Lowers the risk of major adverse cardiovascular events or major adverse limb eventsHR, 0.87 [95% CI, 0.80–0.95]

Randomized trialmedian of 40.6 months13,970 peopleBoth18 to 85 years of agePatients 18 to 85 years of age with history of or at high risk of cardiovascular diseases who were not able to take recommended statin treatment because of intoleranceCirculation, Aug 18, 2026

down: Decreases LDL-C−22.75%

up: Increases uric acid+0.96 mg/dL

Treated cohortmedian follow-up duration of 28 weeks (IQR 23–47 weeks)125 people79.2% were malemean age 62.4 ± 10.1 yearsPatients with CCS, aged ≥18 years, with LDL-C levels ≥ 55 mg/dL despite at least 8 weeks of stable intensive lipid-lowering therapyJournal of clinical medicine, Aug 5, 2026

down: Decreases LDL cholesterol-18.02% (95% CI, -18.83 to -17.21)

Review of trials6,025 people pooledOn top of statin therapyJournal of clinical lipidology, Feb 26, 2026

down: Decreases major adverse cardiovascular events

Randomized trialmedian follow-up 40.6 months13,970 people66 ±9 yearsOlder adults; in patients with elevated steatosis scoresEuropean journal of preventive cardiology, Feb 16, 2026

down: Decreases LDL-C-19% (IQR -36.4% to -3.6%, p < 0.01)

down: Decreases C-reactive protein-34.0% (p < 0.01)

Trial12 weeks180 peoplePatient cohortsmedRxiv, Feb 9, 2026

down: Decreases LDL-C-24.3% (95% CI -27.8 to -20.9)

down: Lowers the risk of major adverse cardiovascular eventsRR 0.81 (95% CI 0.68–0.96)

no change: Has no effect on mortalityRR 0.87 (95% CI 0.53–1.43)

Review of trials22,345 people pooledHypercholesterolemiaAHA Scientific Sessions 2025 abstract, Nov 3, 2025

down: Decreases non-HDL cholesterolMD -15.50 mg/dL; 95% CI -18.95 to -12.04

Review of trials12 weeks3,034 people pooledBothmean 65.3 ± 9.1 (cases) and 66.2 ± 8.8 (controls)Patient cohortsAHA Scientific Sessions 2025 abstract, Nov 3, 2025

down: Lowers the risk of major adverse cardiovascular events-14% (HR 0.86, 95% CI 0.76-0.97)

down: Decreases LDL cholesterol-20.6% (95% CI, -21.7 to -19.6%)

Randomized trial6 months8,217 peopleMonotherapy in statin-intolerant patients without baseline lipid lowering therapiesAHA Scientific Sessions 2025 abstract, Nov 3, 2025